samedan logo
 
 
spacer
home > pmps > summer 2019 > leaving on a jet plane
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Leaving on a Jet Plane

‘Leaving on a jet plane’ is the title of one of John Denver’s greatest hits. However, it is also what an increasing number of pharmaceutical products do every day, when the results of Medicon Valley based R&D, commercialisation, and manufacturing are sent out to make a difference worldwide.

The binational Danish-Swedish life sciences cluster Medicon Valley consists of the Region Zealand, the Danish Capital Region, and the Swedish region Skåne. It is not only host to cutting-edge public and private life sciences R&D in, for instance, oncology, dermatology, diabetes, fertility, and CNS-related diseases, but also the world’s largest insulin manufacturing site owned by Novo Nordisk and located in the Danish city of Kalundborg. Additionally, Medicon Valley-based companies such as LEO Pharma, Baxter, Coloplast, Ferring, and Lundbeck have substantial local production and/or R&D facilities; this makes Copenhagen Airport a central logistics hub and, since it serves Denmark and South Sweden alike, the most important airport in the Nordics from a life sciences perspective.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Petter Hartman is the CEO of Medicon Valley Alliance since June 2015 and holds a Masters in Political Science from the University of Lund, Sweden. At Medicon Valley Alliance, Petter is involved in future strategies for the Medicon Valley region, general management within the public sector, project management, and pharma R&D. Petter comes from a post as Funding Manager at Medicon Valley Alliance. Prior to joining, Petter worked for the Secretariat for Interreg IV A Öresund-Kattegat- Skagerrak, Copenhagen, as a project consultant with special responsibility for issues concerning cross-border relations and labourmarket integration projects.
spacer
Petter Hartman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement